为您找到"
dompe
"相关结果约100,000,000个
Dompe's innovative team developed cenegermin for the treatment of Neurotrophic Keratitis- a rare degenerative eye disease. Find out more. Exscalate. The most advanced intelligent supercomputing platform for drug screening, and the largest enumerated chemical library in the world for preclinical and clinical candidate identification.
"We have redefined our study areas as platforms based on the biological mechanisms to be investigated. For example, in the field of neuronal growth, we are working on neurotrophins, in immunology on diseases such as juvenile diabetes and we are active in pain, Covid and new approaches to drug discovery"
Dompé Farmaceutici is a privately held pharmaceutical company based in Milan.Founded as a compounding pharmacy in 1890 by Piedmontese Onorato Dompé, the company has grown to a global pharmaceutical company with around 900 employees. [1] His son, Sergio Dompe is the current CEO. [1]In 2012, Dompé acquired the eye health-focused Italian pharmaceutical company Anabasis Srl; [2] they went on to ...
Important Safety Information. WARNINGS AND PRECAUTIONS Use with Contact Lens. Contact lenses should be removed before applying OXERVATE® because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cenegermin-bkbj onto the area of the corneal lesion.
Dompé farmaceutici S.p.A. è un'azienda biofarmaceutica italiana, fondata nel 1940 a Milano.Si concentra nei business primary care e biotecnologico e ricerca soluzioni terapeutiche per la cura di malattie rare.I progetti farmaceutici e biotecnologici vengono sviluppati nel polo dell'Aquila.La sede centrale è a Milano, ma Dompé è presente con attività anche a Napoli, Boston, San Francisco ...
Dompé is an international company that produces and markets pharmaceutical and biotech products. It has a 130-year history, a research and production site in L'Aquila, Italy, and a focus on rare diseases and neurotrophins.
The FDA just greenlighted Italian firm Dompé's eye drop Oxervate for the treatment of neurotrophic keratitis (NK), a rare type of eye disease. | The FDA just greenlighted Italian firm Dompé ...
Dompé is conducting Phase 3 trials of cenegermin, a recombinant nerve growth factor, for patients with severe Sjögren's-related dry eye disease, a symptom of the autoimmune disorder Sjögren's. Cenegermin is approved by the FDA for neurotrophic keratitis, a rare eye condition.
Dompe, son of company founder Franco Dompe, said other options also existed, including a reverse merger - or buying a listed business - in the United States, one of the company's key markets.
At Dompé, we take great pride in the unique strengths of our teams and celebrate and reward their outstanding success. We strive for professionals with exceptional skills, yet we ensure everyone has all the tools needed to help them grow.